Biosymtec Medical Inc. is developing a new and unique product and system for personal health monitoring, never before available. 


Biosymtec technology correlates, with a proprietary algorithm, certain sublingual and pulmonary data acquired from an individual upon waking, and within seconds can identify the onset of an illness, usually days before signs, such as fever, are present.

The Biosymtec Monitor and subscription platform captures patient data, shares it with patient physicians, enables prompt medical interventions, and facilitates billing for remote monitoring making the entire experience simple and beneficial to all parties.

Biosymtec Medical's Target Markets

Cystic Fibrosis

According to the data collected by the Cystic Fibrosis Foundation, there are about 30,000 Americans, 3,000 Canadians, and 20,000 Europeans with Cystic Fibrosis. Cystic Fibrosis primarily affects the respiratory and digestive systems in children and young adults.

Source: CDC


16 million in the U.S. alone have COPD and as many as 12 million more have undiagnosed COPD. COPD includes emphysema and chronic bronchitis. Over 60 million people around the world have moderate or severe COPD. COPD costs the U.S. around $30 billion dollars a year in healthcare expenses.

Source: CDC


25 million have asthma, and the numbers are increasing every year. About 12 million with asthma have an asthma attack each year, many of which could have been prevented. Asthma costs the U.S. about $56 billion in medical costs each year.

Source: CDC


Almost 6 million adults in the United States have heart failure. Nearly 10% of all deaths included heart failure as a contributing cause. About half of the people who develop heart failure die within 5 years of diagnosis. Heart failure costs the U.S an estimated $30.7 Billion each year.

Source: CDC

Early Detection, allows for Rapid Response, producing Better outcomes.

© 2019 Biosymtec Medical Inc.